ATE493662T1 - Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker - Google Patents

Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker

Info

Publication number
ATE493662T1
ATE493662T1 AT05075994T AT05075994T ATE493662T1 AT E493662 T1 ATE493662 T1 AT E493662T1 AT 05075994 T AT05075994 T AT 05075994T AT 05075994 T AT05075994 T AT 05075994T AT E493662 T1 ATE493662 T1 AT E493662T1
Authority
AT
Austria
Prior art keywords
mab35
protein
gla
mgp
biomarker
Prior art date
Application number
AT05075994T
Other languages
English (en)
Inventor
Cornelis Vermeer
Original Assignee
Mgp Diagnostics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mgp Diagnostics As filed Critical Mgp Diagnostics As
Application granted granted Critical
Publication of ATE493662T1 publication Critical patent/ATE493662T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05075994T 2004-04-26 2005-04-26 Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker ATE493662T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/832,734 US7700296B2 (en) 1999-07-04 2004-04-26 Diagnostic assay for human Matrix Gla-protein and its use as a biomarker

Publications (1)

Publication Number Publication Date
ATE493662T1 true ATE493662T1 (de) 2011-01-15

Family

ID=34938221

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05075994T ATE493662T1 (de) 2004-04-26 2005-04-26 Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker

Country Status (4)

Country Link
US (2) US7700296B2 (de)
EP (2) EP2261671A2 (de)
AT (1) ATE493662T1 (de)
DE (1) DE602005025559D1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318392A1 (en) * 2006-09-14 2009-12-24 Zora Biosciences Oy Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
US20090276229A1 (en) * 2008-04-30 2009-11-05 Martin Grigorov Methods of monitoring the effect of nutritional products
EP2671574A1 (de) 2012-06-04 2013-12-11 VitaK B.V. Verwendung von Vitamin K zur Verringerung des Allotransplantatversagens und Patientensterblichkeit nach Organtransplantation
US20230233484A1 (en) 2020-04-09 2023-07-27 Emphysema Solutions Bv Use of vitamin k in preventing or counteracting covid-19 disease and diagnostic test to estimate the risk of developing severe disease or mortality by covid-19
CN111607618A (zh) * 2020-06-03 2020-09-01 安徽大学 一种利用突变体使MGP Variant 1对乳腺癌细胞EMT的促进功能丧失的方法
NL2030584B1 (en) 2022-01-17 2023-07-27 Emphysema Solutions Bv Use of vitamin K in preventing or counteracting vaccine-related adverse events, symptoms, morbidity and/or mortality after vaccination against COVID-19 or another coronavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476779A (en) * 1992-09-30 1995-12-19 University Of Maryland At College Park DNA encoding insulin-like growth factor II isolated from rainbow trout
US6311278B1 (en) 1998-09-09 2001-10-30 Sanctum Ltd. Method and system for extracting application protocol characteristics
US6746847B1 (en) 1999-07-04 2004-06-08 Vitak Diagnostic assay for human matrix Gla-protein and its use as a biomarker
US20050186647A1 (en) 2003-11-12 2005-08-25 Ping Gao Methods for identifying or monitoring a patient with increased risk of cardiovascular calcification

Also Published As

Publication number Publication date
EP1591791A2 (de) 2005-11-02
EP2261671A2 (de) 2010-12-15
EP1591791B1 (de) 2010-12-29
EP1591791A3 (de) 2005-11-16
US20100323455A1 (en) 2010-12-23
US20040197830A1 (en) 2004-10-07
DE602005025559D1 (de) 2011-02-10
US8003075B2 (en) 2011-08-23
US7700296B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
EP2783216B1 (de) Immunoassays mit signalverstärkung
RU2003133925A (ru) Способ дифференциальной диагностики деменции альцгеймера и устройство для его проведения
KR20150141952A (ko) 소변 알부민 및 소변 크레아티닌에 대한 신속 검사
MX2009004460A (es) Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos.
WO2005108989A3 (en) Assay for antibodies
Darwish et al. Novel automated flow-based immunosensor for real-time measurement of the breast cancer biomarker CA15-3 in serum
ATE493662T1 (de) Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
Berlina et al. Quantum-dot-based immunochromatographic assay for total IgE in human serum
Schneider et al. Microfluidic antibody affinity profiling of alloantibody-HLA interactions in human serum
Zhang et al. Association of vimentin antibody and other non-HLA antibodies with treated antibody mediated rejection in heart transplant recipients
RU2017114626A (ru) Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике
KR20160120675A (ko) 래피드 정량 진단 키트
DE60037115D1 (de) Diagnostischer test für menschlisches matrix gla-protein und seine verwendung als biomarker
WO2011099435A1 (ja) Ｋｕ８６とその自己抗体との複合体の免疫測定方法、それに用いるキット及びそれを用いた癌判定方法
US20180095090A1 (en) Biomarkers for assessment of preeclampsia
Ourradi et al. Development and validation of novel biomarker assays for osteoarthritis
Timbrell et al. An immunodiagnostic assay for quantitation of specific IgE to the major pollen allergen component, Pas n 1, of the subtropical Bahia grass
Swank et al. A high-throughput microfluidic nano-immunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultra-low volume dried blood samples
WO2006060188A3 (en) Anti-tenascin monoclonal antibody immunoassays and diagnostic kits
KR20100008632A (ko) 폐암 진단 마커 및 키트
US10557857B1 (en) System and method for bone loss assay
US10094833B2 (en) Method and kit for detecting bacterial infection
Vutthikraivit et al. Development and validation of point‐of‐care testing of albuminuria for early screening of chronic kidney disease
WO2022202876A1 (ja) Ｉ型コラーゲンｃ末端テロペプチドの免疫学的分析方法

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties